PCAC July 2026: What the BPC-157, TB-500 and Semax FDA Hearing Means for Peptide Researchers
TL;DR: FDA's PCAC meets 23–24 Jul 2026 to vote on 503A compounding eligibility for BPC-157, TB-500, KPV, MOTS-c, Semax, DSIP & Epitalon.
What Is This Meeting and Why Does It Matter?
On 23 and 24 July 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) will convene at the agency's White Oak Campus in Silver Spring, Maryland — with a virtual attendance option — to evaluate seven research peptides for inclusion on the US 503A bulks list.[1] This is the next formal regulatory step following the April 2026 removal of these compounds from the FDA's 503A Category 2 list, which we covered in our earlier FDA Peptide Reclassification 2026 guide.
The compounds on the agenda span two days and include some of the most widely researched peptides in the field: BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax, and Epitalon. All seven are supplied by Velox Peptides as HPLC-verified research reagents for in vitro use — a legal status that is entirely separate from and unaffected by the PCAC process, which governs US compounding pharmacies only.
For UK researchers, the practical significance is indirect: while this committee cannot change UK law or MHRA regulations, its recommendations shape the global research narrative around these compounds and serve as a meaningful signal about the quality of evidence available for each peptide.
The April 2026 Category 2 Removal: What Led to This Hearing
To understand the July hearing, it helps to know what it follows. The FDA's 503A system divides bulk substances into three categories: those approved for compounding (Category 1), those under evaluation, and those that cannot be compounded (Category 2). From around 2019, a large number of research peptides were placed on the Category 2 list, effectively restricting their use by US compounding pharmacies.
On 15 April 2026, HHS confirmed the withdrawal of nominations for 12 peptides from the 503A Category 2 list, removing them from the prohibited category.[2] The seven peptides now before the PCAC were among them. Removal from Category 2 does not automatically grant compounding permission — it simply clears the first regulatory hurdle. The PCAC hearing on 23–24 July 2026 is the next step: the committee will evaluate whether the evidence base supports adding these substances to the affirmative 503A bulks list.
Day 1 — 23 July 2026: BPC-157, KPV, TB-500 and MOTS-c
The first day of the hearing covers four compounds, each reviewed for both its free base and acetate salt forms, which have different physicochemical properties relevant to compounding formulation.
BPC-157 (Body Protection Compound-157)
BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a sequence found in gastric juice proteins. It is one of the most extensively studied research peptides, with an unusually consistent body of rodent data spanning tendon repair, mucosal healing, angiogenesis, and skeletal muscle research models.[3] A 2025 review in PubMed (PMID: 41476424) examining injectable peptide therapy in orthopaedic settings noted that BPC-157's preclinical evidence base is plausible and well-characterised, while observing that published human data remains limited to small case series without control groups — the central issue the PCAC will examine.[3]
See also: BPC-157 research guide · BPC-157 vs TB-500 comparison
KPV (Lys-Pro-Val)
KPV is a tripeptide — just three amino acids (Lysine, Proline, Valine) — derived from the C-terminal sequence of alpha-melanocyte-stimulating hormone (α-MSH). It has been studied in preclinical models focused on mucosal inflammation, particularly in intestinal tissue models, where it is examined for its interaction with melanocortin receptors expressed in epithelial and immune cells. The small molecular size makes it of interest in oral and mucosal delivery research.
TB-500 (Thymosin Beta-4 Fragment)
TB-500 is a synthetic fragment corresponding to residues 17–23 of thymosin beta-4, a naturally occurring peptide involved in actin polymerisation and cytoskeletal regulation. In preclinical models TB-500 has been studied for its role in promoting angiogenesis (new blood vessel formation) and tissue recovery following injury in cardiac, skeletal muscle, and tendon models. Like BPC-157, published human data remains limited.[3]
MOTS-c
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a mitochondrial-derived peptide (MDP) encoded in the mitochondrial genome — a different origin from most research peptides, which are nuclear-encoded. It has been studied in metabolic research models, with preclinical data from rodent studies suggesting roles in insulin sensitivity, glucose metabolism, and skeletal muscle energy regulation. Research interest has grown since the initial characterisation by Lee et al. in Cell Metabolism (2015).
Day 2 — 24 July 2026: DSIP (Emideltide), Semax and Epitalon
DSIP / Emideltide (Delta Sleep-Inducing Peptide)
DSIP (also called emideltide in the FDA docket) is a neuropeptide first isolated from rabbit cerebral venous blood in 1974 by Monnier et al. The FDA uses the INN "emideltide" as the recommended international non-proprietary name. It is a nine-amino-acid peptide studied in sleep, stress, and neuropeptide signalling research; early human studies from the 1980s and 1990s reported effects on sleep architecture, though these were small and methodologically heterogeneous. The PCAC evaluation will focus on whether the existing safety data package is sufficient for a compounding indication.
Semax
Semax is a synthetic heptapeptide analogue of the ACTH(4–7) sequence (Met-Glu-His-Phe-Pro-Gly-Pro). It was developed in Russia and is a licensed pharmaceutical in several Eastern European markets for use in cerebrovascular research contexts. In preclinical models it has been studied for neuroprotective and cognitive-modulation effects, with mechanisms linked to BDNF (brain-derived neurotrophic factor) signalling and catecholamine regulation. Its established regulatory history in other jurisdictions may provide additional data for the PCAC to consider.
Epitalon
Epitalon (also Epithalon; Ala-Glu-Asp-Gly) is a synthetic tetrapeptide developed from research by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, initially as a synthetic analogue of epithalamin from the pineal gland. It has been studied in preclinical aging research models, with published literature examining telomerase activity, circadian regulation, and lifespan in rodent models. Human data is limited to small Eastern European studies.
How the PCAC Evaluation Process Works
The official FDA advisory committee calendar lists the PCAC meeting at FDA's White Oak Campus, Silver Spring, Maryland, with virtual participation available. The Federal Register notice (Docket FDA-2025-N series) sets out the agenda, docket for public comment, and procedural requirements.
Source: fda.gov — PCAC July 2026
Each compound follows the same structured process at the hearing:
Step 1 — Nominator presentation
The party that nominated the substance for 503A bulks-list review presents its evidence dossier to the committee. This covers the compound's chemistry, manufacturing, existing safety data, and proposed clinical rationale for compounding.
Step 2 — Open public hearing
Members of the public, researchers, patient advocacy groups, and compounding pharmacy representatives may address the committee directly during a designated period. Written comments submitted before 9 July 2026 are provided to committee members in advance.
Step 3 — Committee deliberation and advisory vote
The PCAC members deliberate and vote on whether to recommend inclusion on the 503A bulks list. The vote is advisory only — the FDA is not legally required to follow it. However, PCAC recommendations are a significant input into subsequent FDA rulemaking decisions.
Step 4 — FDA decision and rulemaking
After the meeting, the FDA reviews the committee's recommendation and any public comments in the docket. A positive recommendation may lead the FDA to initiate formal rulemaking (notice-and-comment rulemaking) to add the substance to the 503A bulks list. This process takes additional months to complete.
A compound added to the 503A bulks list is one the FDA has affirmatively recognised as eligible for use in individualised compounded prescriptions by licensed US compounding pharmacies and physicians. This is distinct from full FDA drug approval, which requires separate NDA (New Drug Application) review demonstrating safety and efficacy for a specific indication.
What This Means for UK Researchers
The FDA's 503A compounding system is a US-specific regulatory framework governing US licensed pharmacies and prescribers. It has no direct legal effect on UK researchers, MHRA regulations, or UK research-use supply. BPC-157, TB-500, MOTS-c, Semax, DSIP, KPV, and Epitalon are not controlled substances under UK law and are not scheduled under the Misuse of Drugs Act 1971 or the Medicines Act 1968 in a way that would restrict their supply as research reagents.
Velox Peptides supplies all seven compounds as HPLC-verified (≥99% purity) research reagents for in vitro laboratory use, in accordance with UK research-use law and our Research Use Policy. This status is unchanged regardless of what the PCAC recommends.
That said, the hearing is worth watching for two reasons. First, the PCAC evaluation may surface new published literature or safety data for these compounds that is useful to researchers assessing the evidence base. Second, a positive committee recommendation — and subsequent FDA rulemaking — would signal that the US regulatory apparatus views the available safety data as adequate for a compounding context, which is contextually meaningful for researchers globally who follow these compounds.
References
- US Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. FDA Advisory Committee Calendar. fda.gov
- US Department of Health and Human Services. Removal of 12 peptides from FDA 503A Category 2 list, effective 15 April 2026. Federal Register / HHS announcement. See also: Velox Peptides — FDA Peptide Reclassification 2026.
- Taras JS, Dearden B, Trionfo A, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. PubMed. 2025. PMID: 41476424
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443–454. PMID: 25738459
- Monnier M, Hätt RA. Humoral transmission of sleep. VII. Isolation and characterization of the sleep-delta-inducing peptide. Pflügers Arch. 1974;348(2):165–178. PMID: 4853537
Frequently Asked Questions
What is the FDA PCAC and when does it meet in 2026?
The Pharmacy Compounding Advisory Committee (PCAC) is an FDA advisory body that evaluates bulk drug substances for inclusion on the 503A bulks list — the register of substances that US compounding pharmacies may use under section 503A of the Federal Food, Drug, and Cosmetic Act. The PCAC meets on 23–24 July 2026 at FDA's White Oak Campus in Silver Spring, Maryland (virtual attendance available). Day 1 covers BPC-157, KPV, TB-500, and MOTS-c. Day 2 covers DSIP (Emideltide), Semax, and Epitalon.
Which peptides are being reviewed at the July 2026 PCAC?
Seven peptides are scheduled for review. Day 1 (23 July 2026): BPC-157 (free base and acetate), KPV (free base and acetate), TB-500 (free base and acetate), and MOTS-c (free base and acetate). Day 2 (24 July 2026): Emideltide/DSIP (free base and acetate), Semax, and Epitalon. All seven were removed from FDA 503A Category 2 effective April 2026.
What is the 503A bulks list and why does it matter?
Section 503A of the US Federal Food, Drug, and Cosmetic Act permits licensed pharmacists and physicians to compound drug preparations for individual patients, provided the bulk substances used appear on the FDA's approved bulks list. Inclusion on the 503A bulks list gives FDA affirmative recognition for compounding in individualised prescriptions — but this is a compounding eligibility classification, not full FDA drug approval. The list governs US compounding pharmacies and has no direct bearing on UK or EU research-use supply.
What does a PCAC recommendation mean for BPC-157 and TB-500?
The PCAC will hear presentations from nominators, accept public comments, deliberate, and vote on whether each substance should be recommended for the 503A bulks list. The committee's vote is advisory only — the FDA is not legally required to follow it. A positive recommendation typically triggers FDA rulemaking to formally add the substance to the 503A bulks list, enabling US compounding pharmacies to dispense it under physician prescription. A negative recommendation or deferral does not change the research-use status of these compounds outside the US compounding context.
Does the FDA PCAC decision affect UK research peptide buyers?
No. The FDA's 503A compounding classification governs US compounding pharmacies only. UK researchers purchasing research-use peptides operate under UK law and MHRA regulation, which are fully independent of FDA compounding classifications. BPC-157, TB-500, Semax, DSIP, KPV, MOTS-c, and Epitalon are not controlled substances under UK law and are supplied by Velox Peptides as in vitro research reagents — a status unchanged by whatever the PCAC decides.
What is the public comment deadline for the July 2026 PCAC meeting?
Written comments submitted by 9 July 2026 will be formally provided to PCAC members ahead of the meeting. Comments may be submitted via the FDA docket (FDA-2025-N series). Virtual attendance and public oral comment opportunities are also available at the meeting itself.
